Pages
Products

Lentiviral Vector-Based In Vivo CAR-T Development

Integrated development solutions for targeted lentiviral vector-based in vivo CAR-T therapies — from CAR design and vector engineering to in vivo validation, CMC, and analytical support.

Our integrated workflow connects therapeutic design, targeted LVV engineering, functional evaluation, translational studies, and GMP development to support the progression of in vivo CAR-T candidates toward IND-enabling development.

1CAR & Payload Design

2Targeted LVV Engineering

3In Vitro Validation

4In Vivo Pharmacology

5Process Development

6Analytical & QC Support

01 CAR Discovery & Payload Design

Design and optimize CAR architectures and therapeutic payloads for targeted in vivo T-cell engineering, with a focus on activity, specificity, and translational potential.

Explore Service →

02 Targeted Lentiviral Vector Engineering

Develop and optimize targeted LVV systems for selective T-cell delivery, integrating envelope engineering, targeting strategies, and vector characterization.

Explore Service →

03 In Vitro Transduction & Functional Assessment

Evaluate vector targeting, transduction efficiency, CAR expression, T-cell activation, expansion, and functional activity using relevant in vitro models.

Explore Service →

04 In Vivo CAR-T Pharmacology & Translational Studies

Assess in vivo CAR-T generation, expansion, persistence, biodistribution, pharmacodynamic response, antitumor activity, and safety-related endpoints.

Explore Service →

05 Targeted LVV Process Development & GMP Manufacturing

Translate targeted LVV candidates into scalable manufacturing processes through upstream and downstream process development, analytical characterization, and GMP production.

Explore Service →

06 Analytical & QC

Characterize LVV identity, purity, potency, safety, and critical quality attributes with fit-for-purpose analytical and QC strategies.

Explore Service →

From Target Discovery to Preclinical In Vivo CAR-T Validation

Our integrated pathway connects target discovery, CAR design, targeted LVV engineering, and preclinical validation in a continuous development workflow. This streamlined approach supports systematic evaluation of in vivo CAR-T candidates from early concept through preclinical proof of concept.

Our Development Capabilities

Targeted Delivery Engineering

Engineering LVV systems designed for selective T-cell targeting and efficient in vivo gene delivery.

Translational Evaluation

Integrated in vitro and in vivo models to evaluate CAR-T generation, function, persistence, biodistribution, and pharmacological response.

Process & Manufacturing Development

Development of scalable LVV processes with phase-appropriate analytical characterization and GMP manufacturing support.

Integrated Analytical Support

Analytical strategies covering vector identity, physical and functional titer, purity, potency, safety, and critical quality attributes.

Advance Your In Vivo CAR-T Program with Targeted LVV

From early CAR design to targeted LVV development, translational studies, and GMP manufacturing, our integrated capabilities support the development of next-generation in vivo CAR-T therapies.

Discuss Your Program

Quick Inquiry